Biotech Values

[mcbio]

Here's some discussion of the theory behind this target - obviously this is a high-risk venture though:

Thanks Peter. OMER tends to be involved in some fairly unique projects between this PDE10 inhibitor, unlocking the orphan GPCRs, and the MASP-2 program (http://www.omeros.com/pipeline/masp2.htm ). I just don't tend to think much of their lead drugs for surgery that are effectively reformulations of generic drugs (http://www.omeros.com/pipeline/pharma.htm ). I may take a much closer look at OMER after Phase 3 results are out for these drugs, with my interest increasing if these were to fail and the stock to take a hit.